Researchers must thoroughly plan their experiments to produce the maximum data according to their budget.
This approach can be particularly difficult for immune cell assays that demand a specific cell subset (like cytotoxic CD8+ T-cells), as manual cell isolations from whole blood can result in increased reagent and labor costs.
This cost analysis explores a standard CD8+ T-cell culture initiation protocol to establish the potential labor and material savings from utilizing cryopreserved cell products compared to whole blood as an initial material.
Download the Full Whitepaper
About BioIVT
BioIVT, formerly BioreclamationIVT, is a leading global provider of high-quality biological specimens and value-added services. We specialize in control and disease state samples including human and animal tissues, cell products, blood, and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples.
Our Research Services team works collaboratively with clients to provide in vitro hepatic modeling solutions. And as the world’s premier supplier of ADME-Tox model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and the effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®.